Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[ d ]imidazole series – Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2

In silico investigation of novel 5-benzylidene-2- (arylsulfonylhydrazono)thiazolidine-4-ones as potential inhibitors of mPGES-1 and COX-2.

“…However, while selective COX-2 inhibitors (coccibs) provide a potent anti-inflammatory and analgesic effect without the side effects caused by non-selective COX inhibitors, long-term use of these agents can lead to cardiovascular side effects [7]. Since inhibition of the mPGES-1 enzyme does not block PGI2 production, selective mPGES-1 inhibitors are not expected to cause cardiovascular side effects [8][9][10].…”